For: | Okajima M, Takamura M, Taniguchi T. Landiolol, an ultra-short-acting β1-blocker, is useful for managing supraventricular tachyarrhythmias in sepsis. World J Crit Care Med 2015; 4(3): 251-257 [PMID: 26261777 DOI: 10.5492/wjccm.v4.i3.251] |
---|---|
URL: | https://www.wjgnet.com/2220-3141/full/v4/i3/251.htm |
Number | Citing Articles |
1 |
Naoyuki Matsuda, Osamu Nishida, Takumi Taniguchi, Masaki Okajima, Hiroshi Morimatsu, Hiroshi Ogura, Yoshitsugu Yamada, Tetsuji Nagano, Akira Ichikawa, Yasuyuki Kakihana. Impact of patient characteristics on the efficacy and safety of landiolol in patients with sepsis-related tachyarrhythmia: Subanalysis of the J-Land 3S randomised controlled study. EClinicalMedicine 2020; 28: 100571 doi: 10.1016/j.eclinm.2020.100571
|
2 |
Clemens Gangl, Konstantin A Krychtiuk, Robert Schoenbauer, Walter S Speidl. Landiolol for refractory tachyarrhythmias in the intensive care unit: case reports. European Heart Journal Supplements 2022; 24(Supplement_D): D43 doi: 10.1093/eurheartjsupp/suac026
|
3 |
Rajeev Seecheran, Roshni Narayansingh, Stanley Giddings, Marlon Rampaul, Kurt Furlonge, Kamille Abdool, Neal Bhagwandass, Naveen Anand Seecheran. Atrial Arrhythmias in a Patient Presenting With Coronavirus Disease-2019 (COVID-19) Infection. Journal of Investigative Medicine High Impact Case Reports 2020; 8 doi: 10.1177/2324709620925571
|
4 |
Mariana Floria, Alexandru Florinel Oancea, Paula Cristina Morariu, Alexandru Burlacu, Diana Elena Iov, Cristina Petronela Chiriac, Genoveva Livia Baroi, Celina Silvia Stafie, Magdalena Cuciureanu, Viorel Scripcariu, Daniela Maria Tanase. An Overview of the Pharmacokinetics and Pharmacodynamics of Landiolol (an Ultra-Short Acting β1 Selective Antagonist) in Atrial Fibrillation. Pharmaceutics 2024; 16(4): 517 doi: 10.3390/pharmaceutics16040517
|
5 |
Fabio Guarracino, Andrea Cortegiani, Massimo Antonelli, Astrid Behr, Giandomenico Biancofiore, Alfredo Del Gaudio, Francesco Forfori, Nicola Galdieri, Giacomo Grasselli, Gianluca Paternoster, Monica Rocco, Stefano Romagnoli, Salvatore Sardo, Sascha Treskatsch, Vincenzo Francesco Tripodi, Luigi Tritapepe. The role of beta-blocker drugs in critically ill patients: a SIAARTI expert consensus statement. Journal of Anesthesia, Analgesia and Critical Care 2023; 3(1) doi: 10.1186/s44158-023-00126-2
|
6 |
Felix Eibensteiner, Emmilie Mosor, Daniel Tihanyi, Sonja Anders, Andrea Kornfehl, Marco Neymayer, Julia Oppenauer, Christoph Veigl, Valentin Al Jalali, Hans Domanovits, Patrick Sulzgruber, Sebastian Schnaubelt. The Impact of Chronic Oral Beta-Blocker Intake on Intravenous Bolus Landiolol Response in Hospitalized Intensive Care Patients with Sudden-Onset Supraventricular Tachycardia—A Post Hoc Analysis of a Cross-Sectional Trial. Pharmaceutics 2024; 16(6): 839 doi: 10.3390/pharmaceutics16060839
|
7 |
Shiavax J. Rao, Arjun Kanwal, Amreen Kanwal, Alexandrina Danilov, William H. Frishman. Landiolol: An Ultra-Short-Acting β-Blocker. Cardiology in Review 2024; 32(5): 468 doi: 10.1097/CRD.0000000000000555
|
8 |
Brian W. Johnston, Chung S. Chean, Rui Duarte, Ruaraidh Hill, Bronagh Blackwood, Danny F. McAuley, Ingeborg D. Welters. Management of new onset atrial fibrillation in critically unwell adult patients: a systematic review and narrative synthesis. British Journal of Anaesthesia 2022; 128(5): 759 doi: 10.1016/j.bja.2021.11.016
|
9 |
Gheorghe-Andrei Dan, Anca R Dan, Andreea Ivanescu, Adrian C Buzea. Acute rate control in atrial fibrillation: an urgent need for the clinician. European Heart Journal Supplements 2022; 24(Supplement_D): D3 doi: 10.1093/eurheartjsupp/suac022
|
10 |
Madeleine Perrett, Nisha Gohil, Otilia Tica, Karina V. Bunting, Dipak Kotecha. Efficacy and safety of intravenous beta-blockers in acute atrial fibrillation and flutter is dependent on beta-1 selectivity: a systematic review and meta-analysis of randomised trials. Clinical Research in Cardiology 2024; 113(6): 831 doi: 10.1007/s00392-023-02295-0
|
11 |
Sebastian Rehberg, Michael Joannidis, Tony Whitehouse, Andrea Morelli. Landiolol for managing atrial fibrillation in intensive care. European Heart Journal Supplements 2018; 20(suppl_A): A15 doi: 10.1093/eurheartj/sux039
|
12 |
Bruno Levy, Michel Slama, Ines Lakbar, Julien Maizel, Hiromi Kato, Marc Leone, Motoi Okada. Landiolol for Treatment of New-Onset Atrial Fibrillation in Critical Care: A Systematic Review. Journal of Clinical Medicine 2024; 13(10): 2951 doi: 10.3390/jcm13102951
|
13 |
Péter Radics, Boldizsár Kiss, Enikő Kovács, Dávid Pilecky, Zoltán Ruzsa, Éva Straub, Csaba Fejér, László Gellér, Béla Merkely, Endre Zima. A landiolol alkalmazási lehetőségei a kardiológiai és intenzív terápiás ellátásban. Orvosi Hetilap 2022; 163(2): 53 doi: 10.1556/650.2022.32347
|
14 |
Salwa A. Abuiessa, Sahar M. El-Gowilly, Hanan M. El-Gowelli, Mai M. Helmy, Mahmoud M. El-Mas. Short-lived sensitization of cardiovascular outcomes of postpartum endotoxemia in preeclamptic rats: Role of medullary solitary tract neuroinflammation. European Journal of Pharmacology 2021; 910: 174494 doi: 10.1016/j.ejphar.2021.174494
|
15 |
Yoh Arita, Takatsugu Segawa, Shohei Yamamoto, Shinji Hasegawa. Landiolol is effective for the treatment of tachycardia-induced cardiogenic shock in patients during septic shock therapy. BMJ Case Reports 2017; : bcr-2017-222268 doi: 10.1136/bcr-2017-222268
|
16 |
Sofia Bezati, Antonios Boultadakis, Ioannis Ventoulis, Eftihia Polyzogopoulou, John T. Parissis. Optimal use of intravenous landiolol in acute cardiac care. Expert Review of Cardiovascular Therapy 2023; 21(11): 855 doi: 10.1080/14779072.2023.2277354
|
17 |
Yasuyuki Kakihana, Osamu Nishida, Takumi Taniguchi, Masaki Okajima, Hiroshi Morimatsu, Hiroshi Ogura, Yoshitsugu Yamada, Tetsuji Nagano, Eiichiro Morishima, Naoyuki Matsuda. Efficacy and safety of landiolol, an ultra-short-acting β1-selective antagonist, for treatment of sepsis-related tachyarrhythmia (J-Land 3S): a multicentre, open-label, randomised controlled trial. The Lancet Respiratory Medicine 2020; 8(9): 863 doi: 10.1016/S2213-2600(20)30037-0
|
18 |
Tomáš Janota. (Do we need another intravenous beta-blocker?). Cor et Vasa 2020; 62(6): 625 doi: 10.33678/cor.2020.112
|
19 |
Kengo Ayabe, Tomoyoshi Komiyama, Hiroyuki Takekawa, Honsa Kang, Yasuaki Tsumagari, Miwa Ito, Keiichi Ashikaga, Yoshisato Shibata. Differential Effects of Landiolol in Patients with Atrial Fibrillation and Atrial Tachycardia. Medicina 2024; 60(11): 1782 doi: 10.3390/medicina60111782
|
20 |
Po Huang, Fusheng Liu, Xiao Hu, Bo Li, Xiaolong Xu, Qingquan Liu. Effect of ultrashort-acting β-blockers on 28-day mortality in patients with sepsis with persistent tachycardia despite initial resuscitation: a meta-analysis of randomized controlled trials and trial sequential analysis. Frontiers in Pharmacology 2024; 15 doi: 10.3389/fphar.2024.1380175
|
21 |
Bapi Gorain, Sulagna Dutta, Utpal Nandy, Pallav Sengupta, Hira Choudhury. Frontiers in Pharmacology of Neurotransmitters. 2020; : 107 doi: 10.1007/978-981-15-3556-7_4
|
22 |
Thi Thom Tran, Calypso Mathieu, Magali Torres, Béatrice Loriod, Linh Thuy Lê, Catherine Nguyen, Monique Bernard, Marc Leone, Nathalie Lalevée. Effect of landiolol on sex-related transcriptomic changes in the myocardium during sepsis. Intensive Care Medicine Experimental 2019; 7(1) doi: 10.1186/s40635-019-0263-0
|
23 |
Sebastian Schnaubelt, Felix Eibensteiner, Julia Oppenauer, Daniel Tihanyi, Marco Neymayer, Roman Brock, Andrea Kornfehl, Christoph Veigl, Valentin Al Jalali, Sonja Anders, Barbara Steinlechner, Hans Domanovits, Patrick Sulzgruber. Hemodynamic and Rhythmologic Effects of Push-Dose Landiolol in Critical Care—A Retrospective Cross-Sectional Study. Pharmaceuticals 2023; 16(2): 134 doi: 10.3390/ph16020134
|
24 |
Michihiro Sakai, Satoshi Jujo, Junjiro Kobayashi, Yoshihiko Ohnishi, Masataka Kamei. Use of low-dose β1-blocker for sinus tachycardia in patients with catecholamine support following cardiovascular surgery: a retrospective study. Journal of Cardiothoracic Surgery 2019; 14(1) doi: 10.1186/s13019-019-0966-z
|
25 |
Yujiro Matsuishi, Bryan J Mathis, Nobutake Shimojo, Satoru Kawano, Yoshiaki Inoue. <p>Evaluating the Therapeutic Efficacy and Safety of Landiolol Hydrochloride for Management of Arrhythmia in Critical Settings: Review of the Literature</p>. Vascular Health and Risk Management 2020; : 111 doi: 10.2147/VHRM.S210561
|
26 |
Yahiya Y. Syed. Landiolol: A Review in Tachyarrhythmias. Drugs 2018; 78(3): 377 doi: 10.1007/s40265-018-0883-9
|
27 |
Liam Joseph O'Bryan, Oliver C Redfern, Jonathan Bedford, Tatjana Petrinic, J Duncan Young, Peter J Watkinson. Managing new-onset atrial fibrillation in critically ill patients: a systematic narrative review. BMJ Open 2020; 10(3): e034774 doi: 10.1136/bmjopen-2019-034774
|
28 |
Salwa A. Abuiessa, Mai M. Helmy, Hanan M. El-Gowelli, Sahar M. El-Gowilly, Mahmoud M. El-Mas. Dysregulated ACE/Ang II/Ang1-7 signaling provokes cardiovascular and inflammatory sequelae of endotoxemia in weaning preeclamptic rats. European Journal of Pharmacology 2022; 936: 175344 doi: 10.1016/j.ejphar.2022.175344
|
29 |
信洋 森, 広介 関根, 照彦 高倉. Renal replacement therapy databased development using landiolol in sepsis. Iryou kikigaku (The Japanese journal of medical instrumentation) 2022; 92(5): 525 doi: 10.4286/jjmi.92.525
|
30 |
Martin Unger, Andrea Morelli, Mervyn Singer, Peter Radermacher, Sebastian Rehberg, Helmut Trimmel, Michael Joannidis, Gottfried Heinz, Vladimír Cerny, Pavel Dostál, Christian Siebers, Fabio Guarracino, Francesca Pratesi, Gianni Biancofiore, Massimo Girardis, Pavla Kadlecova, Olivier Bouvet, Michael Zörer, Barbara Grohmann-Izay, Kurt Krejcy, Christoph Klade, Günther Krumpl. Landiolol in patients with septic shock resident in an intensive care unit (LANDI-SEP): study protocol for a randomized controlled trial. Trials 2018; 19(1) doi: 10.1186/s13063-018-3024-6
|